May 12, 2015 – Press Release
Sigma-Aldrich® Corporation (NASDAQ: SIAL) today announced that SAFC® Commercial (www.sigma-aldrich.com/safc), its custom manufacturing services business unit, has completed the expansion of its St. Louis facility to support commercial-scale antibody drug conjugate (ADC) manufacturing. The facility is in final validation and expected to go online as planned in the third quarter of 2015. Once validated, customers will benefit from working with a single supplier from discovery to commercialization.
Designed to meet SafeBridge® category 4 compound handling to safely accommodate usage of highly-active compounds, the St. Louis expansion creates commercial-scale manufacturing capacity for ADCs and other targeted therapies. The expanded capabilities in St. Louis are further enhanced by expanded commercial capacity for highly-active manufacturing and storage at the Company’s Madison, Wis. facility.
SAFC’s offers include cell-line engineering and media, linkers and payloads, along with significant conjugation expertise using both highly-active and non-potent compounds. The St. Louis expansion complements other recent additions in ADC capabilities, including the announcement of SAFC’s ADC ExpressSM service for preclinical ADC and bioconjugation services, and a collaboration with industry leader Baxter BioPharma Solutions for formulation and fill/finish services.
“The ADC market is a growing market, and is expected to expand over the next few years. This strategic expansion is the latest in a series of enhancements in our ADC offering designed to support this important therapeutic area and to help our customers to seamlessly scale ADC production from preclinical to commercial phases,” said Gilles Cottier, President of SAFC. “Our offer can bring customers’ molecules to the clinic faster, with the ease of working with one supplier from start to finish. With the added support of our recently launched ADC Express service, we believe SAFC presents the most comprehensive offer in the contract manufacturing market.”
To learn more about SAFC’s ADC capabilities, visit: http://www.sigmaaldrich.com/safc-adc.
The foregoing release contains forward-looking statements that can be identified by terminology such as “is expected,” “will benefit,” “can bring,” or similar expressions, or by expressed or implied discussions regarding potential future revenues from products derived therefrom. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that expansion of any facility or additions in capacity will enable the Company to achieve any particular levels of revenue in the future. In particular, management's expectations regarding the facility and added capacity could be affected by, among other things, the Company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company's assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich's current Form 10-K on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
About SAFC: SAFC Commercial, the custom manufacturing and services business unit of Sigma-Aldrich Corporation, is recognized as a top 10 global specialty chemicals and biologics supplier. As a trusted manufacturer for the life science and high-technology industries, SAFC works closely with customers to resolve development challenges and accelerate the product pipeline using its global "Centers of Excellence" and dedicated manufacturing facilities. Its rich portfolio includes high-purity inorganic materials for high-tech applications, critical raw materials and extensive biologics safety-testing services for biopharmaceutical manufacturing, and complex, high-potent APIs and key intermediates for pharmaceutical manufacturing. For more information, visit www.sigma-aldrich.com/safc.
About Sigma-Aldrich: Sigma-Aldrich, a leading Life Science and Technology company focused on enhancing human health and safety, manufactures and distributes 250,000 chemicals, biochemicals and other essential products to more than 1.4 million customers globally in research and applied labs as well as in industrial and commercial markets. With three distinct business units - Research, Applied and SAFC Commercial - Sigma-Aldrich is committed to enabling science to improve the quality of life. The Company operates in 37 countries, has approximately 9,300 employees worldwide and had sales of $2.79 billion in 2014. For more information about Sigma-Aldrich, please visit its website at www.sigma-aldrich.com.
©2015 Sigma-Aldrich Co. LLC. All rights reserved. Sigma-Aldrich and SAFC are trademarks of Sigma-Aldrich Co. LLC or its affiliates, registered in the U.S. and other countries.